



Sociedad Española  
de Reumatología -  
Colegio Mexicano  
de Reumatología

# Reumatología Clínica

www.reumatologiaclinica.org



## Original Article

### Direct medical costs and their predictors in the EMAR-II cohort: “Variability in the management of rheumatoid arthritis and spondyloarthritis in Spain”<sup>☆</sup>



Leticia Leon,<sup>a,b,\*</sup> Lydia Abasolo,<sup>a</sup> Benjamin Fernandez-Gutierrez,<sup>a</sup> Juan Angel Jover,<sup>a</sup> Cesar Hernandez-Garcia<sup>c</sup>

<sup>a</sup> Servicio de Reumatología, Hospital Clínico San Carlos, Madrid, Spain

<sup>b</sup> Universidad Camilo José Cela, Madrid, Spain

<sup>c</sup> Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain

#### ARTICLE INFO

##### Article history:

Received 29 March 2016

Accepted 17 September 2016

Available online 20 November 2017

##### Keywords:

Cost  
Rheumatoid arthritis  
Economic impact  
National cohort

#### ABSTRACT

**Objective:** To analyze the resource utilization in rheumatoid arthritis (RA) patients and predictive factors in and patients treated with biological drugs and biologic-naïve.

**Methods:** A cross-sectional study was performed in a sample including all regions and hospitals throughout the country. Sociodemographic data, disease activity parameters and treatment data were obtained. Resource utilization for two years of study was recorded and we made costs imputation. Correlation analyzes were performed on all RA patients and those treated with biological and biological naïve, to estimate the differences in resource utilization. Factors associated with increased resources utilization (costs) attending to treatment was analyzed by linear regression models.

**Results:** We included 1.095 RA patients, 26% male, mean age of  $62 \pm 14$  years. Mean of direct medical costs per patient was  $\text{€}24,291 \pm \text{€}45,382$ . Excluding biological drugs, the average cost per patient was  $\text{€}3742 \pm \text{€}3711$ . After adjustment, factors associated with direct medical costs for all RA patients were biologic drugs ( $P = .02$ ) and disease activity ( $P = .004$ ). In the biologic-naïve group, the predictor of direct medical costs was comorbidity ( $P < .001$ ). In the biologic treatment group predictors were follow-up length of the disease ( $P = .04$ ), age ( $P = .02$ ) and disease activity ( $P = .007$ ).

**Conclusion:** Our data show a remarkable economic impact of RA. It is important to identify and estimate the economic impact of the disease, compare data from other geographic samples and to develop improvement strategies to reduce these costs and increase the quality of care.

© 2016 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

### Costes médicos directos y sus predictores en la cohorte “Variabilidad en el manejo de la artritis reumatoide y las espondiloartritis en España”

#### RESUMEN

**Objetivo:** Estimar los costes médicos directos en los pacientes con artritis reumatoide (AR) y los factores predictores en los pacientes tratados con fármacos biológicos y sin biológicos.

**Métodos:** Se realizó un estudio transversal en una muestra incluyendo pacientes de toda la geografía nacional. Se obtuvieron datos sociodemográficos y de tratamiento. Se registró la utilización de recursos para los 2 años de estudio y se hizo imputación de costes. Se realizaron análisis de correlación en todos los pacientes con AR y en los tratados con y sin biológicos, para estimar las diferencias entre los grupos. Los predictores de costes se analizaron mediante modelos de regresión lineal.

**Resultados:** Se incluyeron 1.095 pacientes con AR, el 26% hombres, con una edad media de  $62 \pm 14$  años. La media de los costes médicos directos por paciente fue de  $24.291 \pm 45.382 \text{€}$ . Excluyendo los fármacos biológicos, el coste medio por paciente fue de  $3.742 \pm 3.711 \text{€}$ . Después de ajustar, los factores predictores

##### Palabras clave:

Coste  
Artritis reumatoide  
Impacto económico  
Cohorte nacional

<sup>☆</sup> Please cite this article as: Leon L, Abasolo L, Fernandez-Gutierrez B, Jover JA, Hernandez-Garcia C. Costes médicos directos y sus predictores en la cohorte “Variabilidad en el manejo de la artritis reumatoide y las espondiloartritis en España”. Reumatol Clin. 2018;14:4–8.

\* Corresponding author.

E-mail address: [leon.hcsc@salud.madrid.org](mailto:leon.hcsc@salud.madrid.org) (L. Leon).

de costes médicos directos para todos los pacientes con AR fueron los fármacos biológicos ( $p=0,00$ ), la comorbilidad ( $p=0,00$ ) y la edad del paciente ( $p=0,01$ ). En el grupo sin biológicos, los predictores fueron la comorbilidad ( $p=0,00$ ) y la edad del paciente ( $p=0,01$ ). En el grupo con biológicos los predictores fueron el sexo del paciente ( $p=0,03$ ) y la actividad de la enfermedad ( $p=0,02$ ).

**Conclusión:** Los datos muestran un notable impacto económico de la AR. Es importante identificar y estimar los factores asociados a mayor coste para desarrollar estrategias de reducción de costes y aumentar la calidad de la atención.

© 2016 Elsevier España, S.L.U.

y Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. Todos los derechos reservados.

## Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory disease with a prevalence of approximately 0.8 (0.3–1.0) per 100 adults. The peak in the onset of the disorder ranges between 55 and 64 years of age.<sup>1–3</sup> As a consequence of this condition, RA patients consume a great deal of health care resources, and the costs are high. Given the cost of treatment and the loss in productivity, this disease has a great impact on society. Studies on the costs of the disease conducted in Europe and the United States estimate a figure of around €4000–€6000 per patient per year.<sup>4–6</sup>

In Spain, the management of inflammatory rheumatic diseases has undergone marked advances due to several factors such as the availability of new treatments, a deeper understanding of the processes and progress in the care of the rheumatic patient.

The increase in the use of biological agents in routine rheumatology practice has raised the direct costs 3 to 6-fold in several European countries.<sup>7,8</sup> However, changes in the patterns of treatment have achieved a decrease in the mean disease activity (Disease Activity Score 28 joints [DAS28]), hospital stays, lost work days and work disability,<sup>9</sup> thus resulting in a reduction in the indirect costs related to the disease.

In a number of studies performed in the 1980s and 1990s,<sup>10–13</sup> the major medical expense was hospital admission, which, in those articles, represented a third of the cost. In later studies, the greatest cost corresponded to the drugs prescribed.<sup>14</sup> This change was associated with a growing percentage of patients treated with biological agents.

The purpose of the study entitled “Variability in the management of rheumatoid arthritis and spondyloarthritis in Spain” (EMAR-II) was to describe variability in terms of health care resource consumption and the use of techniques and treatments and, thus, made it possible to define these changes in this country. Hospitals of different autonomous communities participated in the study, which had a duration of 2 years (Appendix A). This enabled us to recruit a representative cohort of the disease in Spain.

There are few studies on the costs of RA in the biological era, and those that exist have been conducted in settings in which these agents were still little employed. Thus, the objective of our report was to estimate the direct medical costs corresponding to the EMAR-II cohort, analyze factors that may be predictive of those costs and evaluate the predictive factors in 2 distinct subpopulations: patients who were treated with biological agents during the study period and those who did not receive them.

## Material and Methods

### Design, Patient Selection and Data Acquisition

The EMAR-II study (2009–2010) was a cross-sectional study designed to analyze variability in the management of patients with RA in Spain. We established contact with 100 hospitals, 46 of which agreed to participate, whereas 54 chose not to. The sample was composed of the medical records of the RA patients who were

being seen in the rheumatology departments of the Spanish hospitals and had had at least one visit with their rheumatologist over the 2 years prior to the date of the initiation of the study. In order to recruit at the different participating centers, the random sampling was stratified by autonomous community, with the sampling done in 2 stages, by hospital (units of the first stage) and by patients (units of the second stage). To prevent the lack of representativeness associated with the homogeneity of the different sized units of the first stage, the sampling in that stage was done with a probability proportional to size, whereas, in the second stage, we performed randomized equiprobable sampling of the patients from each center. The smallest autonomous communities were grouped with the largest to ensure that all be represented. The data from the 2 preceding years were extracted from the patients' health records and copied on standardized forms, the same for every case, and a handbook was created with instructions on how to fill them out. The data were then introduced into an electronic database designed specifically for this project.

### Study Subjects

RA patients selected for EMAR-II, which had a total of 1272 participants. *Variables:* the following variables were included: (a) sociodemographic variables: patient age and gender; (b) clinical data: time since RA onset, comorbidity, acute phase reactants (erythrocyte sedimentation rate [ESR], C-reactive protein [CRP] or others), composite disease activity indices (DAS, Simplified Disease Activity Index [SDAI] or others), visual analog scales (VAS) with the highest and lowest physician and patient global assessments, evaluation of the functional status in terms of disease activity (functional status according to the American College of Rheumatology and the Health Assessment Questionnaire), and a variable we refer to as disease activity (generated for this study), composed of a DAS28 in active disease ( $\geq 3.2$ ) in 2 visits or a high ESR ( $\geq 50$  mm/h) in 2 measurements or a high subjective physician assessment (SPA) ( $\geq$  moderate level) in 2 visits, and (c) the cost variables assigned to health care resource consumption: number of medical visits to other services, number and types of nonmedical visits, RA-related hospital admissions, orthopedic surgery, ancillary studies (laboratory, diagnostic imaging, others), arthrocentesis, drugs (nonsteroidal anti-inflammatory drugs [NSAID], glucocorticoids, disease-modifying antirheumatic drugs [DMARD], biological agents).

### Data Sources

The direct costs in this study are defined as costs for the Spanish social security system, the primary payer of these expenditures in Spain. The Spanish health care system offers universal coverage financed by taxes that operates mainly within the public sector. The services are free at the point of care, with the exception of the drugs prescribed to people under the age of 65 years, who, in most cases, have to pay 40% of the retail price.

Using the EMAR-II database, we generated a specific database for this study that included data on the RA patients and the costs were




Fig. 1. Distribution of the direct medical costs over the 2-year EMAR-II study.

allocated. Given the large costs involved in the study, we needed to employ several data sources. These were provided by the official gazettes of the Spanish autonomous communities and were published by their health departments or by the Ministry of Health, the Spanish Agency for Consumer Affairs, the Spanish Institute of Health, the Institute of Health Information or other sources, like the Soikos health cost database, version 2.2.<sup>15–23</sup> All of the costs are expressed in 2010 euros.

#### Statistical Analysis

We describe the sociodemographic, clinical and cost variables of the sample utilizing frequency distribution, mean and standard deviation. As the data were not normally distributed, the dependent variable—costs—was transformed to approximate normality. This descriptive analysis was also performed for the group of patients who took biological agents and for those who did not receive those drugs during the study period. The differences between the groups in terms of direct medical costs were estimated using contingency tables and Student's *t* test.

Bivariate and multivariate analyses were carried out in order to estimate the possible predictive factors of the direct medical costs in the entire sample employing linear regression models. We subsequently performed a secondary analysis using linear regression methods to estimate the differences and the predictors of the direct medical costs in the group that received biological agents and in the group that did not. The data shown correspond to a study period of 2 years. The analyses were performed with the Stata 10.0 statistical software package (Stata Corp, College Station, TX, United States).

#### Results

The final study sample consisted of a total of 1095 patients for whom all of the data on medical costs were available.

In all, 26% of the patients included in the study were men. The mean age was  $62 \pm 14$  years. With respect to the clinical characteristics of the sample, the duration of the disease was  $10.2 \pm 8.9$  years. Overall, 49.8% of the patients had some type of associated comorbidity, distributed as follows: nodules (12.16%), Sjögren's syndrome (10.53%), carpal tunnel syndrome (6.82%), Raynaud's phenomenon (2.5%), C1–C2 subluxation (2.5%), pulmonary fibrosis (2.3%), pleuritis (1.4%), vasculitis (0.9%), scleritis (0.9%), Felty's syndrome (0.4%) and amyloidosis (0.15%). The highest DAS28 score during the study period was recorded in patients with low activity ( $DAS \leq 3.2$ ) in 27.76%, moderate activity ( $DAS 3.2–5.1$ ) in 45% and high activity ( $DAS > 5.1$ ) in 27.24%. The mean minimum ESR

was  $15.26 \pm 14.10$  and the maximum values were  $38.30 \pm 27.13$ . The SPA had minimum values of  $15.26 \pm 14.10$  and the maximum values were  $38.30 \pm 27.13$ . Lastly, for the disease activity variable generated for this study (a combination of DAS28 in active disease [ $\geq 3.2$ ] in 2 visits or an elevated ESR [ $\geq 50$  mm/h] in 2 measurements or an elevated SPA [ $\geq$  moderate level] in 2 visits), we found that 26.14% of the patients had high activity and 73.86% of the patients had low activity.

In all, 67.3% of the participants took NSAID during the study period and 67.6% received corticosteroids. Overall, 20.7% of the patients had received 2 or more DMARD simultaneously over the preceding 2 years. The DMARD most widely administered during the study period was methotrexate (59.6%), followed by leflunomide (22.1%), antimalarial drugs (12.2%) and sulfasalazine (3.1%). Altogether, 36.95% of the sample received some type of biological therapy during the study period. The agents most widely used were adalimumab (27.3%), infliximab (20.5%); etanercept 50 mg (19.9%), etanercept 25 mg (12.2%) and rituximab (7.6%).

The costs were calculated using the monetary value assigned to the health services according to the different data sources consulted. The total direct medical cost per patient was  $\text{€}24,291 \pm 45,382$  throughout the 2 years of the study. The total expenditure for drugs (DMARD, biological agents, NSAID, corticosteroids and analgesics) was  $\text{€}19,567 \pm 43,560$ . If we exclude the cost of biological drugs, the mean cost per patient was  $\text{€}3742 \pm 3711$ . The distribution of the costs is shown in Figure 1. There was a statistically significant gender-related difference, with an average cost of  $\text{€}17,330 \pm 1993$  for men and of  $\text{€}26,814 \pm 1720$  for women ( $P = .002$ ).

With respect to differences between the groups, the patients who received biological agents had a significantly higher cost in relation to the following variables: visits to the rheumatologist; visits to the nursing service; orthopedic surgery without prosthesis; orthopedic surgery of the spine; social service counseling; psychology unit; rehabilitation services; complete blood counts; laboratory testing; sedimentation; protein electrophoresis; serology; cultures; rheumatoid factor; ESR; CRP; anti-cyclic citrullinated peptide antibodies; chest radiography; axial bone radiography; magnetic resonance imaging; Mantoux test; pulmonary function tests; arthrocentesis; and hospital admission.

There were no differences in the costs for the other variables evaluated. Although it was not statistically significant, the patients who received biological agents were less costly in terms of visits to other specialists, tests for human leukocyte antigen B27, abdominal radiographs, certain other types of radiographs and abdominal ultrasound.

**Table 1**  
Multiple Linear Regression Analysis of the Direct Medical Costs in the Population of Rheumatoid Arthritis Patients.

	Patients with rheumatoid arthritis			
	$\beta$ coefficient	Standard deviation	t	P
Biological agents	1.23	0.02	50.80	<b>.000</b>
Comorbidity	0.07	0.01	6.77	<b>.000</b>
Disease duration	0.0009	0.001	0.72	.474
Patient age	−0.002	0.0008	−2.50	<b>.012</b>
Patient sex	0.04	0.025	1.59	.112
Disease activity	0.01	0.025	0.64	.524
Constant	3.40	0.05	59.61	.000

Statistically significant values, that is, those with  $P < .05$ , are in boldface.

**Table 2**  
Multiple Linear Regression Analysis of the Direct Medical Costs in Patients Who did not Receive Biological Agents.

	Patients who did not take biological agents			
	$\beta$ coefficient	Standard deviation	t	P
Comorbidity	0.10	0.01	9.02	<b>.000</b>
Disease duration	0.0005	0.001	0.38	.704
Patient age	−0.002	0.0009	−2.23	<b>.026</b>
Patient sex	0.006	0.027	0.23	.821
Disease activity	−0.03	0.031	−1.11	.269
Constant	3.40	0.06	55.39	.000

Statistically significant values, that is, those with  $P < .05$ , are in boldface.

Bivariate linear regression analysis showed that the variables associated with direct medical costs were patient sex—with higher costs for women ( $P = .002$ ), patient age ( $P = .00$ ), disease duration ( $P = .00$ ), disease activity ( $P = .00$ ) and treatment with biological drugs ( $P = .00$ ).

Multivariate regression analysis was subsequently performed with all of the variables that had been significant in the bivariate analysis, which were adjusted for the sociodemographic variables (Table 1). In the analysis of the predictors of medical costs for the sample as a whole, the predictive factors were biological agents ( $P = .00$ ), comorbidity ( $P = .00$ ) and patient age ( $P = .01$ ).

A bivariate model was utilized in the analysis by subgroup. For the group of patients who did not receive biological drugs, the variables associated with costs were comorbidity ( $P = .00$ ) and patient age ( $P = .01$ ). For the group of patients who took biological drugs, the variables that were associated with costs were disease duration ( $P = .02$ ), patient sex—with higher direct medical costs for women ( $P = .01$ )—and disease activity ( $P = .00$ ).

Finally, 2 models of multivariate regression were built, one for each group of patients, including the variables that were statistically significant in the bivariate analysis. In the analysis of the direct medical cost predictors in the group of patients that did not receive biological agents during the study period, the independent predictive factors identified were comorbidity ( $P = .00$ ) and patient age ( $P = .02$ ) (Table 2). In the analysis of the predictors of direct medical costs in the group of patients who took biological drugs during the study period, the independent factors detected were patient sex ( $P = .03$ ) and disease activity ( $P = .02$ ) (Table 3).

## Discussion

This retrospective study calculates the direct costs involving the recourses utilized by the patients. The results of this report provide an extensive characterization of RA patients in Spain. Their distribution in terms of age and sex was similar to that of other published series,<sup>24</sup> the mean age of the patients was somewhat over 60 years of age and 26% were men.

**Table 3**  
Multiple Linear Regression Analysis Of The Direct Medical Costs In Patients Who Received Biological Agents.

	Patients who received biological agents			
	$\beta$ coefficient	Standard deviation	t	P
Comorbidity	0.009	0.02	0.45	.654
Disease duration	0.001	0.002	0.56	.573
Patient age	−0.002	0.001	−1.67	.096
Patient sex	0.104	0.049	2.11	<b>.036</b>
Disease activity	0.09	0.043	2.25	<b>.025</b>
Constant	4.63	0.10	45.60	.000

Statistically significant values, that is, those with  $P < .05$ , are in boldface.

The costs (excluding biological drugs), with a mean of €3742 during the study period, were lower than those reported for patients in other studies, in which the annual cost was around €3980.<sup>25</sup>

It appears to be clear that biological agents are the bulk of these direct medical costs, although other factors have a role, like disease activity, in the case of patients taking biologicals. In individuals who do not receive these drugs, patient age and comorbidities are major predictors of direct medical costs.

There are studies that show that the increase in the cost of therapy produced by the introduction of biological agents has decelerated since 2009<sup>26</sup> since the rate of prescriptions is growing, but more sequentially. This has also resulted in the optimization of the drugs with less rigid protocols that can be better adapted to the characteristics of the patient. Given the trend toward early treatment, it is expected that the costs will stabilize over time.

It seems evident that the direct medical costs of RA patients have risen due to the introduction of new treatments, as well as to the aging of the patients, which is increasing in parallel to the age of the general population. However, although this study does not focus on indirect costs, other reports indicate that they are being compensated by reductions in other costs. In fact, a recent study shows a continuous increase in annual medical costs for patients with RA who were being treated by German rheumatologists between 2002 and 2011, caused by the growing use of biological agents. However, the rise was partially offset by the decrease in the costs of hospital admissions, sick leave and work disability, with a reduction in lost work days and fewer cases of permanent disability.<sup>27</sup>

On interpreting the results of this study, certain limitations must be taken into account. Data were collected for only 2 years and, thus, the interpretation of the findings should be done with caution. Moreover, it should be kept in mind that certain data may not be extractable from the medical records or not be documented, both of which influence the validity of the results.<sup>28</sup> Likewise, the cost data are not exact, but rather are assertions taken at the national level. The costs per patient can be incorrectly estimated, especially because differences related to the community and center were not taken into account. It is important to point out that, because of the type of study, it was impossible to establish the indirect costs associated with work productivity and other causes. Therefore, we were not able to estimate the impact on the indirect costs that could have resulted from a better therapy management or the introduction of biological drugs, as has been seen in other studies.

In conclusion, this study presents a detailed map of the direct medical costs associated with RA patients in Spain. These data may contribute to the understanding and estimation of the economic impact of the disease, to their comparison with data from other geographic areas, to the development of strategies for the reduction of these costs and to an increase in quality of care. Along this line, recommendations on the optimization of drugs and treatment

profiles adapted to the patient are of major importance, as well as the possibility of establishing nurse counseling to instruct patients and broaden their knowledge of the disease, thus reducing medical visits and unnecessary tests in many cases.

### Ethical disclosures

**Protection of human and animal subjects.** The authors declare that no experiments were performed on humans or animals for this investigation.

**Confidentiality of data.** The authors declare that they have adhered to the protocols of their centre of work on patient data publication.

**Right to privacy and informed consent.** The authors must have obtained the informed consent of the patients and/or subjects mentioned in the article. The author for correspondence must be in possession of this document.

### Funding

The EMAR-II study was promoted by the Spanish Society of Rheumatology and financed by the pharmaceutical company AbbVie.

### Conflicts of Interest

The EMAR-II study was financed by the pharmaceutical company AbbVie.

### Appendix A. Components of the EMAR-II Study Group

C. Escudero, N. Chozas, I. Maries, A. Fernandez, F. Medina, I. Ureña, V. Irigoyen, M. Lopez, P. Espiño, S. Manrique, E. Collantes, P. Font, D. Ruiz, M. Granados, M.J. Pozuelo, I. Moreno, J.M. Pina, R. Roselló, C. Vázquez, J. Beltrán, F.J. Manero-Ruiz, A. Pecondón, E. Giménez, F. Jimenez, J. Marzo, M. Medrano, J. Babío, T. Tinturé, S. González, C. Ordás, M.E. García, L. Espadaler, J. Fernandez, J. Fiter, A. Naranjo, S. Ojeda, J. Tornero, J.A. Piqueras, E. Júdez, C. López, J. Medina, G. Iglesias, M. Alvarez, J. Alegre, M.R. Colazo, J.L. Alonso, B. Álvarez, C. Montilla, S. Gómez, R. López, M. Sánchez, S. Castro, S. Ordóñez, D. Boquet, J. Calvet, D. de la Fuente, V. Rios, M. Nolla, A. Martínez-Cristóbal, R. Negueroles, M.L. Muñoz, J. García, F. Gamero, E. del Rincón, E. Pérez-Pampín, L. Fernandez, R. Miguélez, A.M. Ortíz, E. Vicente, S. Pérez Esteban, E. Tomero, A. Casado, M.J. Arias, E. Cuende, C. Bohorquez, J.M. Rodríguez, A. Aragón, J. García, J. Zubieta, A. Gallego, C. Martínez, I. Mateo, A. de Juanes, E. Enríquez, I. Monteagudo, F.J. López-Longo, E. Pagán, M.J. Rubira, P. Mesa, J. Galvez, E. Saiz, C. Tornero, E. Úcar, C. Rodríguez, B. González Álvarez, N. Rivera, F.X. Arasa, S. Bustabad, E. Delgado, J. Maese and R. Veroz.

### References

1. Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, et al. The prevalence of rheumatoid arthritis in the United Kingdom: New estimates for a new century. *Rheumatology (Oxford)*. 2002;41:793–800.
2. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. *Arthritis Res Ther*. 2009;11:229.
3. Guillemain F, Saraux A, Guggenbuhl P, Roux CH, Fardellone P, Le Bihan E, et al. Prevalence of rheumatoid arthritis in France: 2001. *Ann Rheum Dis*. 2005;64:1427–30.

4. Franke LC, Ament AJ, van de Laar MA, Boonen A, Severens JL. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. *Clin Exp Rheumatol*. 2009;27 Suppl. 55:S118–23.
5. Kawatkar AA, Jacobsen SJ, Levy GD, Medhekar SS, Venkatasubramanian KV, Herrinton LJ. Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey. *Arthritis Care Res (Hoboken)*. 2012;64:1649–56.
6. Kvamme MK, Lie E, Kvien TK, Kristiansen IS. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry. *Rheumatology (Oxford)*. 2012;51:1618–27.
7. Modena V, Bianchi G, Roccatello D. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target? *Autoimmun Rev*. 2013;12:835–8.
8. Fautrel B, Verstappen SM, Boonen A. Economic consequences and potential benefits. *Best Pract Res Clin Rheumatol*. 2011;25:607–24.
9. Ziegler S, Huscher D, Karberg K, Krause A, Wassenberg S, Zink A, et al. Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997–2007: results from the National Database of the German Collaborative Arthritis Centres. *Ann Rheum Dis*. 2010;69:1803–8.
10. Yelin E. The costs of rheumatoid arthritis: absolute incremental, and marginal estimates. *J Rheumatol*. 1996;44:47–51.
11. Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell DM, Roth SH. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. *Arthritis Rheum*. 1986;29:488–93.
12. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. *Arthritis Rheum*. 1999;42:1209–18.
13. Clarke AE, Zowall H, Levinton C, Assimakopoulos H, Sibley JT, Haga M, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. *J Rheumatol*. 1997;24:1051–60.
14. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. *Arthritis Rheum*. 2003;48:2750–62.
15. Ruiz-Montesinos MD, Hernández-Cruza B, Ariza-Ariza R, Carmona L, Ballina J, Navarro-Sarabia F. Cost analysis in a cohort of rheumatoid arthritis patients seen in specialized rheumatology consultation in Spain. *Reumatol Clin*. 2005;1:193–9 [in Spanish].
16. Gisbert R, Brosa M. Health Costs Database. Version 2.2. Barcelona: Soikos; 2005.
17. Rubio-Terrés C, Ordovás Baines JP, Pla Poblador R, Martínez Nieto C, Sánchez Garre MJ, Rosado Souvirón MA, et al. Use and cost of biological disease-modifying anti-rheumatic drugs in Spain (PRAXIS study). *Farm Hosp*. 2007;31:78–92.
18. Lamas J, Alonso M, Saavedra J, García-Trío G, Rionda M, Ameijeiras M. Costs of chronic dialysis in a public hospital: Myths and realities. *Nefrología*. 2001;21:283–94 (Referido a: H. Meixoeiro [Vigo]) (Bioquímica básica) [in Spanish].
19. Antoñanzas F, Brenes F, Molero JM, Fernández-Pro A, Huerta A, Palencia R, et al. Cost-effectiveness of the combination of dutasteride and tamsulosin in the treatment of benign prostate hyperplasia in Spain. *Actas Urol Esp*. 2011;35:65–71 [in Spanish].
20. Sánchez-Blanco JJ, Lozano ML, de Arriba F, Vallejo C, Vicente V, Moraleda JM. Peripheral blood hematopoietic stem cells in Spain: a cost analysis. *Med Clin (Barc)*. 2004;123:401–5 [in Spanish].
21. Hospital Lluís Alcanyis. Memoria 2000; 2013. Available from: <http://www.a13.san.gva.es/alcanysis2/m2000/memoria2000.htm> [accessed 06.09.13].
22. San Millán-San Pedro CH. Nota interior. Tarifas por servicios sanitarios prestados a particulares; 2002.
23. Astier MP, Mayordomo JJ, Abad JM, Gómez LI, Tres A. Cost-analysis of high-dose chemotherapy and peripheral blood stem-cell support in patients with solid tumors. *Ann Oncol*. 2000;11:603–6 (Referido a: H. Lozano Blesa [Zaragoza]).
24. Ruiz-Montesinos MD, Hernández-Cruz B, Ariza-Ariza R, Carmona L, Balina J, Navarro-Sarabia F. Costs and quality of life study in rheumatoid arthritis of the Spanish Rheumatology Society. Use of resources of a patient cohort with rheumatoid arthritis seen in specialized rheumatology consultation in Spain. *Reumatol Clin*. 2005;1:142–9 [in Spanish].
25. Ohinmaa AE, Thanh NX, Barnabe C, Martin L, Russell AS, Barr SG, et al. Canadian estimates of healthcare utilization costs for rheumatoid arthritis patients with and without biologics therapies. *Arthritis Care Res*. 2014;66:1319–27.
26. Sokka T, Haugeberg G, Asikainen J, Widding Hansen IJ, Kokko A, Rannio T, et al. Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies. Observational data from two rheumatology clinics. *Clin Exp Rheumatol*. 2013;31:409–14.
27. Huscher D, Mittendorf T, von Hinüber U, Kötter I, Hoese G, Pfäfflin A, et al. German Collaborative Arthritis Centres. Evolution of cost structures in rheumatoid arthritis over the past decade. *Ann Rheum Dis*. 2015;74:738–45.
28. Gomez A, Ciruelo E, de la Cruz J, Serrano JM, Pato E, Gomez-Reino JJ. The loss of reliability in data extraction from clinical histories: the source of the flaws and the usefulness of training. *Med Clin (Barc)*. 1997;108:377–81.